Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Kopetz

Showing results (21-30 of 457) with videos related to

Pageof 46
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Hidden biases in an observational study of bevacizumab beyond progressionScott Kopetz, James L Abbruzzese
Journal of the National Cancer Institute|September 1, 2021
Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?Michael S Lee, Scott Kopetz
Lancet (London, England)|January 28, 2025
Dual checkpoint blockade for microsatellite instability-high colorectal cancerS Daniel Haldar, Scott Kopetz
Oncology (Williston Park, N.Y.)|March 1, 2006
Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in managementScott Kopetz, Paulo M Hoff
Journal of the National Cancer Institute|December 20, 2012
Overcoming resistance to MAPK pathway inhibitorsMichael A Davies, Scott Kopetz
Cancer|June 5, 2015
Coordination of care in colon cancerGeorge J Chang, Scott Kopetz
JAMA Oncology|October 18, 2019
Is the Patient Cured?Harry B Burke, Scott Kopetz
Nature Reviews. Cancer|March 12, 2022
Don't blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemicVan K Morris, Scott Kopetz
Journal of the National Comprehensive Cancer Network : JNCCN|April 14, 2017
Why a One Size Fits All Approach to <i>RAS</i> Might Not Fit Colorectal CancerJonathan M Loree, Scott Kopetz
Clinical Advances in Hematology & Oncology : H&O|December 20, 2021
The emergence of targetable pathways in colorectal cancerIrene S Yu, Scott Kopetz
Pageof 46

Showing results (21-30 of 457) with videos related to

Sort By:
Pageof 46
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Hidden biases in an observational study of bevacizumab beyond progressionScott Kopetz, James L Abbruzzese
Journal of the National Cancer Institute|September 1, 2021
Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?Michael S Lee, Scott Kopetz
Lancet (London, England)|January 28, 2025
Dual checkpoint blockade for microsatellite instability-high colorectal cancerS Daniel Haldar, Scott Kopetz
Oncology (Williston Park, N.Y.)|March 1, 2006
Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in managementScott Kopetz, Paulo M Hoff
Journal of the National Cancer Institute|December 20, 2012
Overcoming resistance to MAPK pathway inhibitorsMichael A Davies, Scott Kopetz
Cancer|June 5, 2015
Coordination of care in colon cancerGeorge J Chang, Scott Kopetz
JAMA Oncology|October 18, 2019
Is the Patient Cured?Harry B Burke, Scott Kopetz
Nature Reviews. Cancer|March 12, 2022
Don't blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemicVan K Morris, Scott Kopetz
Journal of the National Comprehensive Cancer Network : JNCCN|April 14, 2017
Why a One Size Fits All Approach to <i>RAS</i> Might Not Fit Colorectal CancerJonathan M Loree, Scott Kopetz
Clinical Advances in Hematology & Oncology : H&O|December 20, 2021
The emergence of targetable pathways in colorectal cancerIrene S Yu, Scott Kopetz
Pageof 46